Literature DB >> 26121407

ASSOCIATION BETWEEN AQUEOUS HUMOR CXC MOTIF CHEMOKINE LIGAND 13 LEVELS AND SUBFOVEAL CHOROIDAL THICKNESS IN NORMAL OLDER SUBJECTS.

Yoko Nomura1, Hidenori Takahashi, Yujiro Fujino, Hidetoshi Kawashima, Yasuo Yanagi.   

Abstract

PURPOSE: To investigate the association of subfoveal choroidal thickness with intraocular inflammatory cytokines and chemokines.
METHODS: The subjects consisted of 76 eyes of consecutive cataract patients at the Japan Community Health Care Organization Tokyo Shinjuku Medical Center between September 2010 and August 2012. In addition, two autopsy eyes from elderly males were used for immunohistochemical study. Subfoveal choroidal thickness was measured using spectral domain optical coherence tomography before cataract surgery. At the beginning of cataract surgery, a sample of undiluted aqueous humor was manually aspirated and the concentrations of the following cytokines were determined using a multiplex cytokine assay: IP-10, MCP-1, MMP-9, IL-6, IL-10, CXCL1, CXCL12, CXCL13, and CCL11. The association of subfoveal choroidal thickness with intraocular cytokine concentration was analyzed. Expression of CXCL13 was examined in autopsy eyes.
RESULTS: Among these factors, higher concentration of CXCL13 was associated with thicker choroid. In particular, multiple regression analysis showed that the concentration of CXCL13 was associated with subfoveal choroidal thickness (P = 0.001), independently of axial length (P = 0.049). By immunostaining, CXCL13 was clearly detected in choroidal endothelial cells.
CONCLUSION: Aqueous humor concentration of CXCL13 is correlated with subfoveal choroidal thickness in normal subjects.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26121407     DOI: 10.1097/IAE.0000000000000668

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

1.  Aqueous humor inflammatory cytokine levels and choroidal thickness in patients with macular edema associated with branch retinal vein occlusion.

Authors:  Yerim An; Sung Pyo Park; Yong-Kyu Kim
Journal:  Int Ophthalmol       Date:  2021-03-19       Impact factor: 2.031

2.  Subfoveal Choroidal Thickness After Femtosecond Laser-Assisted Cataract Surgery for Age-Related Cataracts.

Authors:  Wan Chen; Hui Chen; Lan Mi; Jing Li; Haotian Lin; Weirong Chen
Journal:  Front Med (Lausanne)       Date:  2022-07-04

3.  Choroidal Thickness in Diabetes and Diabetic Retinopathy: A Swept Source OCT Study.

Authors:  Wei Wang; Sen Liu; Zhihan Qiu; Miao He; Lanhua Wang; Yuting Li; Wenyong Huang
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-04-09       Impact factor: 4.799

4.  Comparison of choroidal thickness in eyes of diabetic patients with eyes of healthy individuals using optical coherence tomography in a tertiary care hospital.

Authors:  Hafsa Hassan; Alyscia Cheema; Muhammad Ali Tahir; Hina Nasreen Nawaz
Journal:  Pak J Med Sci       Date:  2022 Jan-Feb       Impact factor: 1.088

5.  Macular Choroidal Thickness and the Risk of Referable Diabetic Retinopathy in Type 2 Diabetes: A 2-Year Longitudinal Study.

Authors:  Wei Wang; Longyue Li; Jun Wang; Yifan Chen; Xiong Kun; Xia Gong; Daheng Wei; Dongning Wang; Xiaolin Liang; Hua Liu; Wenyong Huang
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-04-01       Impact factor: 4.925

6.  Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy.

Authors:  Shinichi Sakamoto; Hidenori Takahashi; Xue Tan; Yuji Inoue; Yoko Nomura; Yusuke Arai; Yujiro Fujino; Hidetoshi Kawashima; Yasuo Yanagi
Journal:  Br J Ophthalmol       Date:  2017-08-01       Impact factor: 4.638

7.  Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration.

Authors:  Yusuke Arai; Hidenori Takahashi; Satoru Inoda; Xue Tan; Shinichi Sakamoto; Yuji Inoue; Yujiro Fujino; Hidetoshi Kawashima; Yasuo Yanagi
Journal:  PLoS One       Date:  2020-03-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.